Session: 508. Bone Marrow Failure: Acquired: Poster III
Hematology Disease Topics & Pathways:
Translational Research, Aplastic Anemia, Diseases, Human, Animal model
Aims: To investigate whether TGF-β signaling is activated in BM EPCs of AA patients compared with healthy controls(HCs). Moreover, to explore whether activation of TGF-β signaling in EPCs impairs their biological functions in regulating homeostasis of HSC and T cell differentiation. Finally, to determine whether TGF-β inhibition could restore their multi-lineage hematopoiesis and immune balance via repairing BM EPCs in AA.
Methods: A prospective case-control study enrolled AA patients and their age-matched HCs to compare the expression levels of TGF-β1 and TGF-βRI using flow cytometry. BM EPC functions were evaluated by proliferation, apoptosis, migration and tube formation assays. Direct-coculture systems of EPCs and CD34+ or CD3+ cells were used to examine the hematopoiesis-supporting and immune regulation capacity of EPCs, respectively. An impaired EPC model derived from HCs induced by TGF-β1 and a classical AA mice model were established to further validate the role of TGF-β signaling in regulating hematopoiesis and immunological status in vitro and in vivo. Finally, RNA-seq analysis and qRT-PCR were performed to validate previous findings.
Results: Compared to HCs, decreased and dysfunctional EPCs with hyperactive TGF-β signaling, which are characterized as decreased double stained cell numbers, reduced angiogenesis and migration capacities, higher apoptosis ratio, impaired HSC-supporting ability and imbalanced T cell differentiation-supporting ability, were observed in AA patients, which could be improved by TGF-β inhibition. Consistently, the same findings were observed in an impaired EPC model triggered by TGF-β1 in vitro. Furthermore, AA mice presented the damage in BM endothelial cells with activated TGF-β signaling, whereas TGF-β inhibition restored hematopoietic defect and rebalanced T cell subsets via repairing endothelial cells, thus contributing to a better performance in peripheral blood including increased erythroid and megakaryocytic lineages. Mechanismly, RNA-seq and qRT-PCR analysis further validated TGF-β signaling is involved in BM EPC dysfunction in AA patients.
Summary/Conclusion: We found for the first time that dysfunctional BM EPCs with hyperactive TGF-β signaling are involved in AA, whereas inhibition of TGF-β could promote multi-lineage hematopoiesis recovery and immune balance in AA via repairing dysfunctional EPCs. Our study suggests TGF-β inhibitors, including luspatercept, might be a potential therapeutic strategy for AA patients, which provides a rationale for further clinical trials in AA patients to validate our preliminary findings in the future.
Disclosures: No relevant conflicts of interest to declare.